TNONW · Insider Trading
Tenon Medical, Inc. Warrant
Every open-market purchase and sale reported by TNONW officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-05 | Wyatt D. Geist | Chief Innovation Officer | A | +136,401 | — |
| 2026-05-05 | Nathaniel A. Grawey | Chief Commercial Officer | A | +68,201 | — |
| 2026-03-05 | Kevin Williamson | Chief Financial Officer | M | +1,041 | — |
| 2026-01-05 | Steven M Foster | CEO and President | M | +140,936 | — |
| 2026-01-05 | Stephen Hochschuler | Director | MIXED | +7,405 | −$3.10K |
| 2026-01-05 | Ivan Howard | Director | MIXED | +7,405 | −$3.09K |
| 2026-01-05 | Robert K Weigle | Director | MIXED | +7,319 | −$3.17K |
| 2026-01-05 | Richard Ferrari | Director | M | +64,478 | — |
| 2026-01-05 | Richard Ginn | Chief Technology Officer | MIXED | +79,151 | −$44.11K |
| 2026-01-05 | Kristine M Jacques | Director | M | +10,729 | — |
| 2026-01-05 | Kevin Williamson | Chief Financial Officer | MIXED | +40,469 | −$17.24K |
| 2025-12-29 | Robert K Weigle | Director | M | +156 | — |
| 2025-12-29 | Ivan Howard | Director | M | +156 | — |
| 2025-12-22 | Kristine M Jacques | Director | A | +1,750 deriv. | — |
| 2025-12-19 | Kevin Williamson | Chief Financial Officer | M | +2,083 | — |
| 2025-11-18 | Wyatt D. Geist | Chief Innovation Officer | Buy | +19,455 | — |
| 2025-11-18 | Steven M Foster | CEO and President | Buy | +19,455 | — |
| 2025-11-18 | Nathaniel A. Grawey | Chief Commercial Officer | Buy | +101,167 | — |
| 2025-10-15 | Steven M Foster | CEO and President | A | +281,872 deriv. | — |
| 2025-10-15 | Kristine M Jacques | Director | A | +20,293 deriv. | — |
| 2025-10-15 | Ivan Howard | Director | A | +21,464 deriv. | — |
| 2025-10-15 | Richard Ferrari | Director | A | +128,957 deriv. | — |
| 2025-10-15 | Richard Ginn | Chief Technology Officer | A | +253,153 deriv. | — |
| 2025-10-15 | Kevin Williamson | Chief Financial Officer | A | +117,974 deriv. | — |
| 2025-10-15 | Robert K Weigle | Director | A | +21,464 deriv. | — |
| 2025-10-15 | Stephen Hochschuler | Director | A | +21,464 deriv. | — |
| 2023-06-15 | Steven M Van Dick | Chief Financial Officer | Buy | +50,000 | +$13.65K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Wyatt D. Geist | Chief Innovation Officer | 644,735 | $3.48K |
| Nathaniel A. Grawey | Chief Commercial Officer | 482,865 | $2.61K |
| Steven M Foster | CEO and President | 163,814 | $885 |
| Richard Ginn | Chief Technology Officer | 133,015 | $718 |
| Richard Ferrari | Director | 70,764 | $382 |
| Kevin Williamson | Chief Financial Officer | 43,593 | $235 |
| Robert K Weigle | Director | 10,965 | $59 |
| Kristine M Jacques | Director | 10,146 | $55 |
| Ivan Howard | Director | 8,462 | $46 |
| Stephen Hochschuler | Director | 7,938 | $43 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TNONW quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.